Clinical Trials
15 trialsNCT02386800 2026-05-27
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
NCT07379125 2026-05-22
Therapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Phase 1 Recruiting
NCT01962636 2026-05-20
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT02493530 2026-05-19
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT07469891 2026-05-14
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Phase 1 Recruiting
NCT05320198 2026-05-13
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
Phase 1/2 Recruiting
NCT06661915 2026-05-13
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02506933 2026-05-11
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04817007 2026-05-08
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT05467800 2026-05-07
Study of Canakinumab in Patients With Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 2 Active not recruiting
NCT05835466 2026-05-06
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT04771572 2026-05-05
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
Phase 1 Recruiting
NCT04888741 2026-05-05
MoTD
University of Birmingham
Phase 2 Recruiting
NCT06313593 2026-05-04
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT07394153 2026-05-04
PACRIMYEL
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Phase 2 Recruiting